Novel Strategies in the Treatment of Pulmonary Arterial Hypertension

Author(s): Rosalinda Madonna, Nino Cocco

Journal Name: Current Drug Targets

Volume 17 , Issue 7 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Pulmonary arterial hypertension (PAH) is a pathophysiological condition characterized by increased pulmonary vascular resistance (PVR), initially due to abnormal pulmonary vasoconstriction in response to endothelial injury. Recent studies confirmed the key role of endothelin (ET)-1 in the vasoconstriction and remodeling of pulmonary microcirculation during PAH. In responders patients, classical treatments for PAH are prostanoids, phosphodiesterase (PDE)-5 inhibitors and endothelin receptor antagonists (ERAs), which target prostaglandin I2, nitric oxide and endothelin pathways, respectively. Randomised, placebo-controlled trials have shown that ERAs improves haemodynamic parameters of the pulmonary circulation, functional capacity and clinical outcome in patients affected by PAH. Here, we will review the definition, classification and pathophysiology of PH. Furthermore, we will provide an up-to-date overview of currently recommended diagnostic and therapeutic work-up in PAH.

Keywords: Antagonists of endothelin receptor, PDE-5 inhibitors, prostanoids, pulmonary hypertension.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 12 April, 2016
Page: [817 - 823]
Pages: 7
DOI: 10.2174/1389450116666150722140424
Price: $65

Article Metrics

PDF: 38
PRC: 1